Perceptions of Counterfeit Medicines: Only 12% of Americans Feel They Have Enough Information

- A study conducted with 1,500 Americans in July 2015 examined perceived risks of counterfeit medicines¹ -

Bridgewater, NJ, November 20, 2015 / PR Newswire /
Sanofi announced today the results of a new study examining perceptions of the risks associated with counterfeit medicines. Conducted in July 2015, the study sheds light on Americans’ perceptions of counterfeit medicines. The findings show that only 12% of respondents feel that they have enough information on counterfeit medicines, and in most cases, are more likely to associate counterfeiting with consumer goods rather than medicines.

“Counterfeit medicines are a crime against public health and a growing global crisis that affects all types of medical products and any therapeutic indication. They can cause ineffective treatment, sometimes serious side effects, and in the worst cases, the patient’s death,” says Geoffroy Bessaud, Associate Vice President Anti-Counterfeit Coordination, Sanofi. “The findings of this study demonstrate that the burden is still too poorly perceived by populations as a whole, and underline the need for the public at large to be better informed about the risks involved.”

By the Numbers: A Counterfeit Information Shortfall  

• Only 15% of American respondents made the connection between counterfeiting and medicines, while 54% linked the issue more with apparel and 43% with luxury goods.
• More than half of Americans (53%) said they had never heard of counterfeit medicines, and a vast majority (82%) felt that they had never been exposed to counterfeit drugs.
• Fifty-four percent of Americans considered that the danger from counterfeit drugs was undisputable, while 40% felt that it was potential.
• Forty-one percent of respondents said they had no information about counterfeit medicines, and only 12% felt that they had been given sufficient information.

Purchasing Medicines Abroad: A Major Risk
With typical foresight, 77% of all Americans travel with their own medicines, and almost 50% keep these products in their carry-on luggage whenever they fly (47%). As most of them feel that buying medicines abroad is a risky business, only 16% of US travelers actually do it, and 78% of them only buy from pharmacies. Under these conditions, 70% of Americans feel safe about buying, although this feeling of security varies according to destination: 83% when buying in Europe, but only 50% when purchases are made in Asia.

Sanofi: Actively Committed to the Fight Against Counterfeit Medicines
Sanofi has introduced three levels of protection for its medicinesto defend the integrity and tamper-proof seal of each box, and to ensure product authentication and traceability. This level of precaution goes well beyond regulatory obligations.

Sanofi set up a central coordination unit as early as 2007, assembling the internal centers of expertise that are potentially affected by fake drugs: Industrial Affairs, Safety, Medical and Regulatory Affairs, Legal, Public Affairs and Communication. This operational and territorial grid is conducive to greater responsiveness and allows the implementation of concrete actions in the fight against counterfeit medicines.

In 2008, Sanofi created the Central Anti-Counterfeiting Laboratory (LCAC), located at a pharmaceutical site in the city of Tours to analyze suspected counterfeit products. Approximately 4,000 samples are sent to the laboratory each year from all over the world, forwarded by health authorities or seized by police or customs authorities.

The company is also developing platforms designed to alert the general public by way of a website that aims to provide information and advice to raise vigilance over fake medicines and a mobile app for travelers called “travel tips.”

Lastly, Sanofi actively cooperates with national and international authorities to identify illicit platforms and to help take down illegal networks that threaten public health and safety with counterfeit medicines.

Impact of Counterfeiting

• Trafficking in fake medicines was estimated to be worth $200 billion in 2014 versus $75 billion in 2010.²
• Sixty-two percent of tablets purchased on the Internet in 2011 were apparently counterfeit medicines.³
• Ninety-six percent of online sales sites for medicines are purportedly illegal and more than 50% of medicines purchased from websites that conceal their physical address are probably counterfeit drugs.⁴
• Each year, approximately 100,000 to 1 million deaths occur due to counterfeit medicines.⁵
• The estimated figure is 10% of the pharmaceutical market worldwide around $200 billion.⁶

About Sanofi
Sanofi, a global healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients’ needs. Sanofi has core strengths in diabetes solutions, human vaccines, innovative drugs, consumer healthcare, emerging markets, animal health and Genzyme. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).

Sanofi is the holding company of a consolidated group of subsidiaries and operates in the United States as Sanofi US. For more information on Sanofi US, please visit http://www.sanofi.us and http://www.news.sanofi.us/social-media or call 1-800-981-2491.

The full findings from the survey are available upon request.

¹ Results from the Happycurious opinion poll conducted for Sanofi in July 2015, an online questionnaire with a sample of
² IRACM (research institute for counterfeit drugs)
³ European Alliance for Access to Safe Medicines
⁴ WHO, 2012
⁵ Interpol, 2013
⁶ WHO